Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Director's Dealing

22 Jan 2019 17:15

RNS Number : 8101N
Accrol Group Holdings PLC
22 January 2019
Β 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Β 

22 January 2019

Accrol Group Holdings plc

(AIM: ACRL)Β 

Β 

Director's Dealing

Β 

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter,Β announces that, Dan Wright, Executive Chairman of Accrol has today purchased 400,000Β ordinary shares of Β£0.001 each ("Ordinary Shares") at a price of 15.86p per Ordinary Share. Following this purchase, he now holds 2,220,308 Ordinary Shares representing 1.14% of the current Issued Share Capital of the Company.

Β 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dan Wright

Β 

2

Reason for the notification

a)

Position/status

Executive Chairman

Β 

b)

Β 

Initial notification /Amendment

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Β 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of Β£0.001

Β 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

15.86p

Β 

Volume(s)

400,000

Β 

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

22 January 2018

f)

Place of the transaction

London Stock Exchange, AIM

Β 

Β 

Enquiries:

Β 

Β 

For further information, please contact:

Β 

Β 

Β 

Accrol Group Holdings plc

Β 

Dan Wright, Executive Chairman

+44 (0) 1254 278 844

Gareth Jenkins, Chief Executive Officer

+44 (0) 1254 278 844

Β 

Β 

Zeus Capital Limited (Nominated Adviser & Broker)Β 

Β 

Dan Bate / Andrew Jones

+44 (0) 161 831 1512

Dominic King / John Goold

+44 (0) 203 829 5000

Β 

Β 

Belvedere Communications Limited

Β 

Cat Valentine (cvalentine@belvederepr.com)

+44 (0) 7715 769 078

Keeley Clarke (kclarke@belvederepr.com)

Β 

+44 (0) 7967 816 525

Llew Angus (langus@belvederepr.com)

+44 (0) 7407 023 147

Β 

Notes to Editors

Β 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK.Β 

Β 

Accrol operates from three sites:

Β 

Β· A manufacturing, storage and distribution facility in Blackburn;

Β· A facial tissue plant, also in Blackburn; and

Β· A manufacturing, storage and distribution facility in Leyland.

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHBRGDBBBDBGCD
Date   Source Headline
18th May 202111:00 amRNSPrice Monitoring Extension
18th May 20219:06 amRNSSecond Price Monitoring Extn
18th May 20219:00 amRNSPrice Monitoring Extension
18th May 20217:00 amRNSTrading Update
9th Apr 20217:00 amRNSAcquisition of highly scalable wet wipes business
8th Apr 20216:04 pmRNSCorrection: TR-1
8th Apr 20215:58 pmRNSCorrection: TR-1
30th Mar 20217:00 amRNSTR-1
18th Mar 20213:23 pmRNSTR-1
5th Mar 20217:11 amRNSImplementation of LTIP and PDMR dealing
14th Jan 20217:00 amRNSPDMR Dealings
12th Jan 20217:00 amRNSHalf Year Results
7th Jan 20217:00 amRNSOnline HY 21 Investor Presentation
17th Dec 20207:00 amRNSNotice of Half Year Results
15th Dec 20207:00 amRNSOnline Investor Presentation
14th Dec 202011:05 amRNSSecond Price Monitoring Extn
14th Dec 202011:00 amRNSPrice Monitoring Extension
14th Dec 20209:05 amRNSSecond Price Monitoring Extn
14th Dec 20209:00 amRNSPrice Monitoring Extension
11th Dec 20208:51 amRNSTR-1
2nd Dec 20207:00 amRNSAppointment of Chief Financial Officer
27th Nov 202012:48 pmRNSTR-1
26th Nov 20207:00 amRNSTR-1
25th Nov 20207:00 amRNSCompletion of Acquisition
24th Nov 20201:54 pmRNSTR-1
24th Nov 20201:44 pmRNSTR-1
24th Nov 202011:28 amRNSTR-1
24th Nov 202010:54 amRNSTR-1
24th Nov 20207:00 amRNSPDMR Dealing
23rd Nov 20208:00 amRNSAdmission of Shares & Total Voting Rights
20th Nov 202011:32 amRNSResult of General Meeting
20th Nov 20207:00 amRNSResult of Open Offer
6th Nov 202011:55 amRNSTR-1
4th Nov 20205:13 pmRNSPosting of Circular
3rd Nov 20207:00 amRNSConfirmation of Successful Placing
2nd Nov 20204:59 pmRNSAcquisition and Launch of ABB
2nd Nov 20207:00 amRNSCOVID-19 Business Update
27th Oct 20202:44 pmRNSResult of AGM
25th Sep 20208:00 amRNSNotice of AGM and Posting of Accounts
2nd Sep 20207:00 amRNSAudited Final Results
25th Aug 20207:00 amRNSNotice of Results and Online Investor Presentation
22nd May 202012:40 pmRNSTR-1
21st May 20202:25 pmRNSTR-1
6th May 20207:00 amRNSTrading Update
25th Mar 202010:19 amRNSTR-1
23rd Mar 202011:35 amRNSTR-1
17th Mar 20207:00 amRNSAppointment of Joint Broker
4th Mar 20207:00 amRNSTR-1
3rd Mar 20209:41 amRNSTR-1
29th Jan 20207:00 amRNSDirector's Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.